Literature DB >> 12044506

Hormone receptor status in primary breast cancer--time for a consensus?

G C Wishart1, M Gaston, A A Poultsidis, A D Purushotham.   

Abstract

In a previous study, we demonstrated wide variability in the access to oestrogen receptor (ER) measurement, patient selection, choice of technique and the cut-off point for positivity. The aim of this study was to update information on the current use of ER and progesterone receptor (PR) measurement in the United Kingdom (UK). Questionnaires, asking about availability, use and technique of ER and PR measurement, were returned from 170 (74%) units in the UK. Where ER positivity was determined using the percentage of cells staining positive (33%), the absolute cut-off point for positivity varied widely from 5 to 80% of cells. Of the 170 responding units, 107 (63%) felt that PR measurement was important. This study confirms considerable variability in both the technique of ER measurement and the absolute cut-off point for positivity (5-80%). It is essential that a consensus be reached regarding the choice of technique, as well as the threshold for positivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044506     DOI: 10.1016/s0959-8049(01)00304-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  PPARγ antagonist GW9662 induces functional estrogen receptor in mouse mammary organ culture: potential translational significance.

Authors:  Rajendra G Mehta; Xinjian Peng; Sarbani Roy; Michael Hawthorne; Amit Kalra; Fatouma Alimirah; Rajeshwari R Mehta; Levy Kopelovich
Journal:  Mol Cell Biochem       Date:  2012-09-24       Impact factor: 3.396

2.  A new day dawns: women without oestrogen or is a balance best?

Authors:  V Craig Jordan
Journal:  Breast Cancer Res       Date:  2002-09-10       Impact factor: 6.466

3.  Predicting aggressive outcome in T1N0M0 breast cancer.

Authors:  P Kronqvist; T Kuopio; M Nykänen; H Helenius; J Anttinen; P Klemi
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.